vs
Side-by-side financial comparison of OLIN Corp (OLN) and PACS Group, Inc. (PACS). Click either name above to swap in a different company.
OLIN Corp is the larger business by last-quarter revenue ($1.7B vs $1.4B, roughly 1.2× PACS Group, Inc.). PACS Group, Inc. runs the higher net margin — 4.4% vs -8.6%, a 13.0% gap on every dollar of revenue. On growth, PACS Group, Inc. posted the faster year-over-year revenue change (18.4% vs -0.4%). Over the past eight quarters, PACS Group, Inc.'s revenue compounded faster (20.5% CAGR vs 0.9%).
Olin Corporation is an American manufacturer of ammunition, chlorine, and sodium hydroxide. The company traces its roots to two companies, both founded in 1892: Franklin W. Olin's Equitable Powder Company and the Mathieson Alkali Works. Accidents at Olin chemical plants have exposed employees and nearby residents to health hazards.
OLN vs PACS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.7B | $1.4B |
| Net Profit | $-143.2M | $59.7M |
| Gross Margin | 1.9% | — |
| Operating Margin | -9.4% | 7.0% |
| Net Margin | -8.6% | 4.4% |
| Revenue YoY | -0.4% | 18.4% |
| Net Profit YoY | -1517.8% | 3022.5% |
| EPS (diluted) | $-1.25 | $0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.7B | $1.4B | ||
| Q3 25 | $1.7B | $1.3B | ||
| Q2 25 | $1.8B | $1.3B | ||
| Q1 25 | $1.6B | $1.3B | ||
| Q4 24 | $1.7B | $1.1B | ||
| Q3 24 | $1.6B | $1.0B | ||
| Q2 24 | $1.6B | $981.4M | ||
| Q1 24 | $1.6B | $934.3M |
| Q4 25 | $-143.2M | $59.7M | ||
| Q3 25 | $43.7M | $52.4M | ||
| Q2 25 | $-2.8M | $51.0M | ||
| Q1 25 | $1.2M | $28.5M | ||
| Q4 24 | $10.1M | $1.9M | ||
| Q3 24 | $-25.2M | $15.6M | ||
| Q2 24 | $72.3M | $-10.9M | ||
| Q1 24 | $47.8M | $49.1M |
| Q4 25 | 1.9% | — | ||
| Q3 25 | 10.7% | — | ||
| Q2 25 | 7.9% | — | ||
| Q1 25 | 9.0% | — | ||
| Q4 24 | 9.4% | — | ||
| Q3 24 | 8.5% | 17.1% | ||
| Q2 24 | 14.5% | 22.3% | ||
| Q1 24 | 12.7% | 21.2% |
| Q4 25 | -9.4% | 7.0% | ||
| Q3 25 | 4.8% | 6.4% | ||
| Q2 25 | 2.0% | 6.2% | ||
| Q1 25 | 2.7% | 3.8% | ||
| Q4 24 | 2.8% | 1.7% | ||
| Q3 24 | 1.0% | 2.2% | ||
| Q2 24 | 8.3% | 0.1% | ||
| Q1 24 | 5.9% | 8.6% |
| Q4 25 | -8.6% | 4.4% | ||
| Q3 25 | 2.6% | 3.9% | ||
| Q2 25 | -0.2% | 3.9% | ||
| Q1 25 | 0.1% | 2.2% | ||
| Q4 24 | 0.6% | 0.2% | ||
| Q3 24 | -1.6% | 1.5% | ||
| Q2 24 | 4.4% | -1.1% | ||
| Q1 24 | 2.9% | 5.3% |
| Q4 25 | $-1.25 | $0.42 | ||
| Q3 25 | $0.37 | $0.32 | ||
| Q2 25 | $-0.01 | $0.31 | ||
| Q1 25 | $0.01 | $0.17 | ||
| Q4 24 | $0.10 | $-0.03 | ||
| Q3 24 | $-0.21 | $0.10 | ||
| Q2 24 | $0.62 | $-0.07 | ||
| Q1 24 | $0.40 | $0.38 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.6M | $197.0M |
| Total DebtLower is stronger | $2.8B | $353.2M |
| Stockholders' EquityBook value | $1.8B | $946.8M |
| Total Assets | $7.3B | $5.6B |
| Debt / EquityLower = less leverage | 1.55× | 0.37× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.6M | $197.0M | ||
| Q3 25 | — | $355.7M | ||
| Q2 25 | — | $294.2M | ||
| Q1 25 | — | $287.5M | ||
| Q4 24 | $175.6M | $157.7M | ||
| Q3 24 | — | $49.5M | ||
| Q2 24 | — | $73.4M | ||
| Q1 24 | — | $81.2M |
| Q4 25 | $2.8B | $353.2M | ||
| Q3 25 | $3.0B | — | ||
| Q2 25 | $3.0B | — | ||
| Q1 25 | $3.0B | — | ||
| Q4 24 | $2.7B | $411.9M | ||
| Q3 24 | $2.8B | — | ||
| Q2 24 | $2.8B | — | ||
| Q1 24 | $2.7B | — |
| Q4 25 | $1.8B | $946.8M | ||
| Q3 25 | $2.0B | $871.3M | ||
| Q2 25 | $2.0B | $806.8M | ||
| Q1 25 | $2.0B | $750.2M | ||
| Q4 24 | $2.0B | $709.6M | ||
| Q3 24 | $2.1B | $660.0M | ||
| Q2 24 | $2.1B | $572.1M | ||
| Q1 24 | $2.2B | $128.0M |
| Q4 25 | $7.3B | $5.6B | ||
| Q3 25 | $7.6B | $5.6B | ||
| Q2 25 | $7.7B | $5.5B | ||
| Q1 25 | $7.7B | $5.5B | ||
| Q4 24 | $7.6B | $5.2B | ||
| Q3 24 | $7.5B | $4.5B | ||
| Q2 24 | $7.7B | $3.9B | ||
| Q1 24 | $7.6B | $3.9B |
| Q4 25 | 1.55× | 0.37× | ||
| Q3 25 | 1.52× | — | ||
| Q2 25 | 1.52× | — | ||
| Q1 25 | 1.50× | — | ||
| Q4 24 | 1.34× | 0.58× | ||
| Q3 24 | 1.34× | — | ||
| Q2 24 | 1.31× | — | ||
| Q1 24 | 1.24× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $321.2M | $-3.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | -0.06× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $321.2M | $-3.4M | ||
| Q3 25 | $26.7M | $204.8M | ||
| Q2 25 | $212.3M | $52.6M | ||
| Q1 25 | $-86.0M | $150.2M | ||
| Q4 24 | $141.7M | $64.6M | ||
| Q3 24 | $189.9M | $209.2M | ||
| Q2 24 | $90.6M | $34.8M | ||
| Q1 24 | $81.0M | $58.8M |
| Q4 25 | — | — | ||
| Q3 25 | $-44.4M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $-147.4M | — | ||
| Q4 24 | $90.7M | — | ||
| Q3 24 | $146.6M | — | ||
| Q2 24 | $34.1M | — | ||
| Q1 24 | $36.7M | — |
| Q4 25 | — | — | ||
| Q3 25 | -2.6% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -9.0% | — | ||
| Q4 24 | 5.4% | — | ||
| Q3 24 | 9.2% | — | ||
| Q2 24 | 2.1% | — | ||
| Q1 24 | 2.2% | — |
| Q4 25 | — | — | ||
| Q3 25 | 4.2% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.7% | — | ||
| Q4 24 | 3.1% | — | ||
| Q3 24 | 2.7% | — | ||
| Q2 24 | 3.4% | — | ||
| Q1 24 | 2.7% | — |
| Q4 25 | — | -0.06× | ||
| Q3 25 | 0.61× | 3.91× | ||
| Q2 25 | — | 1.03× | ||
| Q1 25 | -71.67× | 5.28× | ||
| Q4 24 | 14.03× | 33.78× | ||
| Q3 24 | — | 13.39× | ||
| Q2 24 | 1.25× | — | ||
| Q1 24 | 1.69× | 1.20× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OLN
| Chlorinechlorinederivativesandothercoproducts | $456.2M | 27% |
| Causticsoda | $400.2M | 24% |
| Militaryandlawenforcement | $304.6M | 18% |
| Epoxyresins | $194.9M | 12% |
| Aromaticsandallylics | $164.4M | 10% |
| Commercial | $144.8M | 9% |
PACS
Segment breakdown not available.
